Clinical quantitative flow cytometry is a new technology that utilizes specialized antibody staining techniques and fluorescent standards to quantitate antibody binding to different cell populations within a sample. The Flow Cytometry Unit uses this technique to quantitate tumor cell antibody binding capacity in patients undergoing various antibody based therapies. The flow cytometric assays are performed in place of previous studies using radioactively labeled antibodies. The flow cytometric assays are more rapid, make the use of radioactivity unnecessary and are performed on 100 uL of blood instead of 25mL. The data collected is also more precise and improves the ability of NCI investigators to compare antibody binding to tumor cells to treatment response. Quantitation of fluorescent antibody binding immediately post therapy also allows precise determination of saturation of antigen sites with non labeled therapeutic antibody. As the majority of NCI lymphoma and leukemia protocols include antibody based therapy in their regimens, this is a tremendous resource for NCI investigators. Antibody binding quantitation is not provided by reference laboratories.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Scientific Cores Intramural Research (ZIC)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Salem, Dalia Abdel-Raouf; Korde, Neha; Venzon, David J et al. (2018) Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Leuk Lymphoma 59:178-186
Kreitman, Robert J; Stetler-Stevenson, Maryalice; Jaffe, Elaine S et al. (2016) Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. Clin Cancer Res 22:310-8
Niemann, Carsten U; Herman, Sarah E M; Maric, Irina et al. (2016) Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Clin Cancer Res 22:1572-82
Skarzynski, Martin; Niemann, Carsten U; Lee, Yuh Shan et al. (2016) Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. Clin Cancer Res 22:86-95
Lee, Daniel W; Kochenderfer, James N; Stetler-Stevenson, Maryalice et al. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517-28
Farooqui, Mohammed Z H; Valdez, Janet; Martyr, Sabrina et al. (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16:169-76
Sun, Clare; Tian, Xin; Lee, Yuh Shan et al. (2015) Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood :
Tembhare, Prashant R; Yuan, Constance M; Venzon, David et al. (2014) Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 38:371-6
Korde, Neha; Carlsten, Mattias; Lee, Min-Jung et al. (2014) A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99:e81-3
Manasanch, Elisabet E; Braylan, Raul; Stetler-Stevenson, Maryalice et al. (2014) Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leuk Lymphoma 55:1402-3

Showing the most recent 10 out of 35 publications